The Securities and Exchange Board of India (SEBI) has approved the initial public offering (IPO) of two major companies—Belrise Industries and Paramesu Biotech. With these approvals, these companies are set to raise a total of INR 2,750 crore. Of this, Belrise Industries IPO is planning to raise INR 2,150 crore, while Paramesu Biotech IPO is planning to raise INR 600 crore.
Belrise Industries IPO
Belrise Industries, a Pune-based automotive original equipment manufacturer (OEM), has received approval from SEBI to bring IPO. Founded in 1988, the company develops safety-focused and engineering solutions that are useful for two-wheelers, three-wheelers, four-wheelers, and commercial and agricultural vehicles.
Belrise Industries’ product portfolio includes metal chassis systems, polymer components, suspension systems, body-in-white components, and exhaust systems. Its special feature is that its products are powertrain-agnostic, that is, it can work for both electric vehicles and vehicles with internal combustion engines.
Strong Financial Position and Market Presence
Belrise Industries financially performed well. As of FY 2024, the company’s annual turnover was INR 7,484.2 crore. The company has more than 15 manufacturing plants in 7 states and employs more than 15,000 employees. Apart from this, the company also exports its products outside India to countries like Austria, Slovakia, the United Kingdom, Japan, and Thailand.
Belrise Industries IPO Details and Use of Funds
Belrise Industries IPO is entirely based on a fresh issue of equity shares, with no offer for sale (OFS). The company will use the INR 1,618 crore raised from the IPO to repay its debt or pay down the advance. The company had a debt of INR 2,463 crore as of June 2024. The remaining amount will be used for corporate functions and business expansion.
Paramesu Biotech IPO: India’s agro-processing industry will get a boost
Paramesu Biotech, a leading manufacturer of maize-based specialty products, has also received approval for IPO from SEBI. Based in Andhra Pradesh, the company maintains a strong presence in the domestic and international markets.
Currently, Paramesu Biotech is operating with an installed production capacity of 800 tonnes per day (TPD) and its production capacity utilization reached 93%, which reflects its efficiency and growing demand in the market.
Parmesu Biotech IPO Structure and Capital Allocation
Parmesu Biotech IPO will consist of a fresh issue of shares worth INR 520 crore, while shares worth INR 80 crore will be sold through an offer for sale (OFS) by the promoter company Unimark Business Solutions.
The company will use this capital as follows:
- ✅ Production Capacity Expansion: A new plant with a capacity of 1,200 tonnes per day (TPD) will be set up in Madhya Pradesh with INR 330 crore. It aims to meet the growing demand for maize-based products and further strengthen the company’s market position.
- ✅ Debt Repayment: INR 85 crore will be used to repay the company’s existing debt, thereby improving its financial position.
- ✅ General Corporate Requirements: The remaining amount will be invested in operational activities and other business initiatives.
These IPOs will be closely watched by investors and market analysts, as both companies are focusing on strong financial position, debt reduction, production capacity expansion, and market leadership in their respective sectors.
IPO Performance 2025
In the first two months of 2025, a total of ten Mainboard IPOs were listed in the Indian markets. These IPOs cumulatively raised INR 15,983.05 crore. Out of these 10 IPOs, three IPOs delivered negative returns. The average listing returns stand at 17.53%. It is quite low compared to IPOs listed in December 2024.
The SME landscape is not affected by ongoing market turmoil. As many as 39 IPOs were listed from 1 January to 28 February 2025. Out of these 39, 13 IPOs landed in negative territory. The average listing returns stand at 18.60%. These IPOs cumulatively raised INR 1,827.94 crore from the market. For more details related to IPO GMP, and Live Subscription stay tuned to IPO Central.